GFAP and Alzheimer disease: We found that Gfap was dramatically upregulated across age groups (Figure 3A; likelihood ratio test [LRT] statistic = 106.321, FDR = 1.28E−18), similar to results from another study reporting age-dependent (12–18 months) upregulation of hippocampal Gfap in tau (CaMKII-MAPT P301L) and amyloid (APP/PSEN1) mouse models (Matarin et al., 2015) and paralleling the astrogliosis observed in human AD brain (Liddelow et al., 2017, Panter et al., 1985).